AHNAK and urinary bladder carcinoma: Previous studies have demonstrated that NAT10 promotes cisplatin resistance in bladder cancer by indirectly facilitating DNA damage response (DDR) through post-transcriptional regulation of AHNAK mRNA stability [46].